MedPath

GABA and Beta-cell Regeneration

Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Registration Number
NCT04375020
Lead Sponsor
Ministry of Health and Population, Egypt
Brief Summary

GABA(gamma-Aminobutyric acid) may be used for decreasing anti-gad antibodies and leads beta-cell regeneration.

Detailed Description

100 patients with type I diabetes were in 2 groups, had been monitored in a private clinic, number 50 each group, with 30 females and 20 males after the written consent of all patients.

All the patients Lied between 18-25 years old with 5-10 years of diabetes onset.

The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.

The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.

In the first group;the investigator measured fasting c peptide levels before and after 6 months of GABA 750mg daily.Also,the investigator measured anti gad antibodies before and after 6 months of treatment.

In the second group,the investigator measured c peptide levels and anti-gad antibodies at the beginning of the trial and after 6 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • type 1 diabetes patients age from 18 to 25 years on basal bolus insulin
Exclusion Criteria

thyroid problems liver disease kidney disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
group1 on GABAGABAThe first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
Primary Outcome Measures
NameTimeMethod
gaba decrease anti gad antibodies6 months

gaba 750 mg daily for type 1 diabetes patients

gaba improve c peptide levels6 months

gaba 750 mg pe day for type 1 diabetes patients

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mahmoud Younis

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath